Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background and Purpose: A non‐psychoactive phytocannabinoid, cannabidiol (CBD), shows promising results as an effective potential antiepileptic drug in some forms of refractory epilepsy. To elucidate the mechanisms by which CBD exerts its anti‐seizure effects, we investigated its effects at synaptic connections and on the intrinsic membrane properties of hippocampal CA1 pyramidal cells and two major inhibitory interneurons: fast spiking, parvalbumin (PV)‐expressing and adapting, cholecystokinin (CCK)‐expressing interneurons. We also investigated whether in vivo treatment with CBD altered the fate of CCK and PV interneurons using immunohistochemistry. Experimental Approach: Electrophysiological intracellular whole‐cell recordings combined with neuroanatomy were performed in acute brain slices of rat temporal lobe epilepsy in in vivo(induced by kainic acid) and in vitro(induced by Mg 2+‐free solution) epileptic seizure models. For immunohistochemistry experiments, CBD was administered in vivo(100 mg·kg−1) at zero time and 90 min post status epilepticus, induced with kainic acid. Key Results: Bath application of CBD (10 μM) dampened excitability at unitary synapses between pyramidal cells but enhanced inhibitory synaptic potentials elicited by fast spiking and adapting interneurons at postsynaptic pyramidal cells. Furthermore, CBD restored impaired membrane excitability of PV, CCK and pyramidal cells in a cell type‐specific manner. These neuroprotective effects of CBD were corroborated by immunohistochemistry experiments that revealed a significant reduction in atrophy and death of PV‐ and CCK‐expressing interneurons after CBD treatment. Conclusions and Implications: Our data suggest that CBD restores excitability and morphological impairments in epileptic models to pre‐epilepsy control levels through multiple mechanisms to reinstate normal network function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex
The Petilla Interneuron Nomenclature Group (PING) (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2402 · Cited by 1,491
McGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Adult Neurogenesis in the Hippocampus: From Stem Cells to Behavior
Gonçalves, J. T., Schafer, S. T., & Gage, F. H. (2016) · Cell · doi:10.1016/j.cell.2016.10.021 · Cited by 1,122 · cited 5×
“While the established CBD actions via CB1 receptors are few, it could be postulated that the proneurogenic effects of CBD in the reported results are a consequence of sequential activation GPCRs and CB1 receptors.”
BackgroundInfluentialDe Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: g protein-coupled receptors
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13878 · Cited by 588 · cited 1×
“…in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c).”
MethodJiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527 · cited 1×
“For example, neurogenesis in both embryonic and cultured adult hippocampal neural stem and progenitor cells has been shown via the activation of GPCRs, CB1 receptors and ERK signalling by CBD and other synthetic cannabinoids (Jiang et al., 2005).”
BackgroundPhytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · cited 3×
“One particular area of recent interest to researchers and clinicians has been the potential use of non-psychoactive phytocannabinoids such as cannabidiol (CBD) or its analogue cannabidivarin, also known as GWP42006 (Hill et al., 2012a; Bialer et al., 2015), in the treatment of epilepsy, particularly the more refractor…”
Background
Cited by
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Petrache, A. L., Rajulawalla, A., Shi, A., Wetzel, A., Saito, T., Saido, T. C., Harvey, K., & Ali, A. B. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz016 · Cited by 124
“4A,B), which was very similar to previous observations made in epileptic tissue (Khan et al. 2018).”
BackgroundMethodResultSelf-citationKaneko, K., Currin, C. B., Goff, K. M., Wengert, E. R., Somarowthu, A., Vogels, T. P., & Goldberg, E. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110580 · Cited by 72
“While new pharmacological therapies for DS have emerged, including cannabidiol (CBD) (Kaplan et al., 2017; Khan et al., 2018) and fenfluramine (Ceulemans et al.”
Metadata
- Authors
- Khan, A. A., Shekh‐Ahmad, T., Khalil, A., Walker, M. C., & Ali, A. B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2018-04-17
- Volume
- 175
- Issue
- 11
- Pages
- 2097-2115
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2792630499
- Cited by
- 84
- References
- 12
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.